Company profile: Egen
1.1 - Company Overview
Company description
- Provider of safe, efficient delivery systems for the manufacture of nucleic acid and anti-cancer drugs and for creating products to treat human diseases, offering synthetic biocompatible delivery vehicles to deliver therapeutic genes, inhibitory RNA (siRNA & shRNA), and small molecules.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Egen
Santaris Pharma
HQ: Denmark
Website
- Description: Provider of RNA-targeted therapy discovery and development using proprietary LNA chemistry through its LNA Drug Platform and Drug Discovery Engine; a privately held, clinical-stage biopharmaceutical company focused on highly specialized, targeted drug development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Santaris Pharma company profile →
Akouos
HQ: United States
Website
- Description: Provider of AAV vector-based gene therapies to restore and preserve hearing in genetically defined patient populations, addressing causes from single gene mutations to ototoxic drug exposure and aging. Offers AK-OTOF, a gene therapy targeting sensorineural hearing loss due to otoferlin mutations, and the Resonate Program, no-cost genetic testing with optional counseling for auditory neuropathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akouos company profile →
Biogazelle
HQ: Belgium
Website
- Description: Provider of genomic testing solutions and expert laboratory services in nucleic acid quantification—including gene expression, mutation, and copy number analysis—and antisense oligonucleotide screening to support development of diagnostics and therapeutics. Offers customized workflows for clinically relevant samples, from liquid biopsies to fixed tissues.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biogazelle company profile →
Kate Therapeutics
HQ: United States
Website
- Description: Provider of AAV-based gene therapies targeting genetically defined muscle and heart diseases, supported by the DELIVER capsid engineering platform for evolving tissue-targeted AAV variants, MyoAAV muscle-tropic capsids for skeletal and cardiac delivery, and cargo technologies to enhance regulation, targeting, and safety.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kate Therapeutics company profile →
Spark Therapeutics
HQ: United States
Website
- Description: Provider of potentially curative, one-time gene therapy treatments for genetic diseases, including investigational programs such as SPK-8011 for hemophilia A, fidanacogene elaparvovec (SPK-9001) for hemophilia B, SPK-3006 for Pompe disease, and gene therapies targeting Stargardt and Huntington’s diseases, plus AAV-based research programs for the retina, liver, and central nervous system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spark Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Egen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Egen
2.2 - Growth funds investing in similar companies to Egen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Egen
4.2 - Public trading comparable groups for Egen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →